EUCTR2008-005826-35-IT进行中（未招募）不适用
A multicenter, double-blind, extension trial of two parallel dose groups of Plant cell expressed recombinant human glucocerebrosidase (prGCD) in patients with Gaucher disiease. - PB-06-003
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Completion of Protocol PB-06-001
- •The patient signs an informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Currently taking another experimental drug for any condition
- •Presence of severe neurological signs and symptoms, defined as complete ocular paralysis, overt myoclonus or history of seizures, characteristic of neuronopathic Gaucher disease
- •Pregnant or nursing
- •Presence of any medical, emotional, behavioral or psychological condition that in the judgment of the Investigator would interfere with the patient?s compliance with the requirements of the study.
研究者
相似试验
进行中（未招募）
不适用
A Multicenter, Double-Blind, Extension Trial of Two Parallel Dose Groups of Plant Cell Expressed Recombinant Human Glucocerebrosidase (prGCD) in Patients With Gaucher DiseaseGaucher diseaseEUCTR2008-005826-35-Outside-EU/EEAProtalix Biotherapeutics30
进行中（未招募）
1 期
A Multicenter, Double-Blind, Extension Trial of Two Parallel Dose Groups of Plant Cell Expressed Recombinant Human Glucocerebrosidase (prGCD) in Patients with Gaucher DiseaseGaucher DiseaseEUCTR2008-005826-35-GBProtalix Biotherapeutics30
进行中（未招募）
不适用
A double-blind, placebo-controlled multi-centre trial of memantine in patients with Parkinsons’ disease dementia or dementia with Lewy bodies - MEMDLBPDDParkinsons disease (PD)and dementia with Lewy bodies (DLB) are both common disease of the elderly. The majority of patients who survive for more than 10 years with PD eventually develope dementia (PDD). The brain changes and clinical presentations of PDD and DLB are similar. The clinical characteristics are cognitive impairment with pronounced visuospatial and executive impairment, visual hallucinations, parkinsonism, fluctuations in cognition and REM sleep disorder.EUCTR2005-004109-27-SEeuropsychiatric clinic60
已完成
2 期
To evaluate the safety and efficacy of DAC HYP in subjects with Multiple Sclerosis who have completed treatment in study 205MS201 (SELECT).CTRI/2010/091/001093Biogen Idec600
进行中（未招募）
1 期
Clinical trial to assess the efficacy and safety of Montelukast in patients with erosive / inflammatory arthrosis of the handsErosive / inflammatory arthrosis of the handsMedDRA version: 20.0Level: LLTClassification code 10003416Term: ArthrosisSystem Organ Class: 100000004859EUCTR2021-001465-20-ESaboratorios Farmalíder S.A.280